Andrade Bruno G N, Cuadrat Rafael R C, Tonetti Fernanda Raya, Kitazawa Haruki, Villena Julio
Adapt Centre, Munster Technological University (MTU), T12 P928 Cork, Ireland.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), 13125 Berlin, Germany.
Biosci Microbiota Food Health. 2022;41(3):94-102. doi: 10.12938/bmfh.2022-009. Epub 2022 Mar 29.
On March 11, 2020, the World Health Organization declared a pandemic of coronavirus infectious disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and imposed the biggest public health challenge for our civilization, with unforeseen impacts in the subsequent years. Similar to other respiratory infections, COVID-19 is associated with significant changes in the composition of the upper respiratory tract microbiome. Studies have pointed to a significant reduction of diversity and richness of the respiratory microbiota in COVID-19 patients. Furthermore, it has been suggested that , and are associated with severe COVID-19 cases, while and are significantly more abundant in asymptomatic subjects or with mild disease. These results have stimulated the search for new microorganisms from the respiratory microbiota with probiotic properties that could alleviate symptoms and even help in the fight against COVID-19. To date, the potential positive effects of probiotics in the context of SARS-CoV-2 infection and COVID-19 pandemics have been extrapolated from studies carried out with other viral pathogens, such as influenza virus and respiratory syncytial virus. However, scientific evidence has started to emerge demonstrating the capacity of immunomodulatory bacteria to beneficially influence the resistance against SARS-CoV-2 infection. Here we review the scientific knowledge regarding the role of the respiratory microbiota in viral infections in general and in the infection caused by SARS-CoV-2 in particular. In addition, the scientific work that supports the use of immunomodulatory probiotic microorganisms as beneficial tools to reduce the severity of respiratory viral infections is also reviewed. In particular, our recent studies that evaluated the role of immunomodulatory strains in the context of SARS-CoV-2 infection are highlighted.
2020年3月11日,世界卫生组织宣布由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)大流行,这给我们的文明带来了最大的公共卫生挑战,并在随后几年产生了不可预见的影响。与其他呼吸道感染类似,COVID-19与上呼吸道微生物群组成的显著变化有关。研究指出,COVID-19患者呼吸道微生物群的多样性和丰富度显著降低。此外,有人提出,[此处原文缺失具体内容]与严重COVID-19病例有关,而[此处原文缺失具体内容]在无症状受试者或轻症患者中明显更为丰富。这些结果促使人们从呼吸道微生物群中寻找具有益生菌特性的新微生物,这些微生物可以缓解症状,甚至有助于抗击COVID-19。迄今为止,益生菌在SARS-CoV-2感染和COVID-19大流行背景下的潜在积极作用是从对其他病毒病原体(如流感病毒和呼吸道合胞病毒)进行的研究中推断出来的。然而,科学证据已开始出现,证明免疫调节细菌有能力有益地影响对SARS-CoV-2感染的抵抗力。在此,我们综述了关于呼吸道微生物群在一般病毒感染,特别是在SARS-CoV-2引起的感染中的作用的科学知识。此外,还综述了支持使用免疫调节益生菌微生物作为减轻呼吸道病毒感染严重程度的有益工具的科学研究。特别是,我们突出了最近评估免疫调节[此处原文缺失具体菌株名称]菌株在SARS-CoV-2感染背景下作用的研究。